ATE475650T1 - Positive allosterische chinolon-m1- rezeptormodulatoren - Google Patents
Positive allosterische chinolon-m1- rezeptormodulatorenInfo
- Publication number
- ATE475650T1 ATE475650T1 AT06838942T AT06838942T ATE475650T1 AT E475650 T1 ATE475650 T1 AT E475650T1 AT 06838942 T AT06838942 T AT 06838942T AT 06838942 T AT06838942 T AT 06838942T AT E475650 T1 ATE475650 T1 AT E475650T1
- Authority
- AT
- Austria
- Prior art keywords
- positive allosteric
- quinolone
- compounds
- receptor
- receptor modulators
- Prior art date
Links
- 230000003281 allosteric effect Effects 0.000 title abstract 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title 1
- 102000017927 CHRM1 Human genes 0.000 abstract 4
- 101150073075 Chrm1 gene Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940126027 positive allosteric modulator Drugs 0.000 abstract 1
- 150000007660 quinolones Chemical class 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04J—MULTIPLEX COMMUNICATION
- H04J3/00—Time-division multiplex systems
- H04J3/02—Details
- H04J3/06—Synchronising arrangements
- H04J3/0635—Clock or time synchronisation in a network
- H04J3/0638—Clock or time synchronisation among nodes; Internode synchronisation
- H04J3/0658—Clock or time synchronisation among packet nodes
- H04J3/0661—Clock or time synchronisation among packet nodes using timestamps
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L63/00—Network architectures or network communication protocols for network security
- H04L63/14—Network architectures or network communication protocols for network security for detecting or protecting against malicious traffic
- H04L63/1441—Countermeasures against malicious traffic
- H04L63/1458—Denial of Service
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L63/00—Network architectures or network communication protocols for network security
- H04L63/12—Applying verification of the received information
- H04L63/123—Applying verification of the received information received data contents, e.g. message integrity
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Computer Security & Cryptography (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Computer Networks & Wireless Communication (AREA)
- Signal Processing (AREA)
- General Engineering & Computer Science (AREA)
- Computer Hardware Design (AREA)
- Computing Systems (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Data Exchanges In Wide-Area Networks (AREA)
- Control Of Eletrric Generators (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74223405P | 2005-12-05 | 2005-12-05 | |
| US78927206P | 2006-04-04 | 2006-04-04 | |
| PCT/US2006/046262 WO2007067489A1 (en) | 2005-12-05 | 2006-12-04 | Quinolone m1 receptor positive allosteric modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE475650T1 true ATE475650T1 (de) | 2010-08-15 |
Family
ID=37963841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06838942T ATE475650T1 (de) | 2005-12-05 | 2006-12-04 | Positive allosterische chinolon-m1- rezeptormodulatoren |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8389545B2 (de) |
| EP (1) | EP1963271B1 (de) |
| JP (1) | JP5192389B2 (de) |
| AT (1) | ATE475650T1 (de) |
| AU (1) | AU2006322045A1 (de) |
| CA (1) | CA2631917A1 (de) |
| DE (1) | DE602006015851D1 (de) |
| TW (1) | TW200840814A (de) |
| WO (2) | WO2007067489A1 (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008002621A2 (en) | 2006-06-28 | 2008-01-03 | Merck & Co., Inc. | Benzyl-substituted quinolone m1 receptor positive allosteric modulators |
| CA2711487A1 (en) * | 2008-01-25 | 2009-07-30 | Merck Sharp & Dohme Corp. | Quinolizidinone m1 receptor positive allosteric modulators |
| EP2252299B1 (de) * | 2008-02-15 | 2014-03-19 | Merck Sharp & Dohme Corp. | Kondensierte pyridon-m1-rezeptor-positive allosterische modulatoren |
| EP2268280B1 (de) * | 2008-03-21 | 2013-04-24 | Merck Sharp & Dohme Corp. | Positive allosterische Chinolizidinon-M1-Rezeptor-Modulatoren |
| AU2009241392A1 (en) | 2008-05-01 | 2009-11-05 | Merck Sharp & Dohme Corp. | 4-oxo-1,4-dihydroquinoline M1 receptor positive allosteric modulators |
| EP2312949B1 (de) * | 2008-08-12 | 2013-08-28 | Merck Sharp & Dohme Corp. | Positive allosterische n-heterozyklische m1-rezeptormodulatoren |
| US8278453B2 (en) | 2008-10-06 | 2012-10-02 | Merck Sharp & Dohme Corp. | Quinolizidinone M1 receptor positive allosteric modulators |
| WO2010047990A1 (en) | 2008-10-23 | 2010-04-29 | Merck Sharp & Dohme Corp. | Fused heterocyclic m1 receptor positive allosteric modulators |
| CA2750708A1 (en) * | 2009-02-23 | 2010-08-26 | Merck Sharp & Dohme Corp. | Pyrazolo [4,3-c] cinnolin-3-one m1 receptor positive allosteric modulators |
| WO2010123716A1 (en) * | 2009-04-20 | 2010-10-28 | Merck Sharp & Dohme Corp. | Heterocyclic fused cinnoline m1 receptor positive allosteric modulators |
| WO2011041143A1 (en) * | 2009-10-01 | 2011-04-07 | Merck Sharp & Dohme Corp. | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS |
| WO2011062853A1 (en) * | 2009-11-20 | 2011-05-26 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
| KR101494059B1 (ko) | 2009-12-17 | 2015-02-16 | 머크 샤프 앤드 돔 코포레이션 | 퀴놀린 아미드 ｍ1 수용체 양성 알로스테릭 조절제 |
| WO2011137049A1 (en) | 2010-04-30 | 2011-11-03 | Merck Sharp & Dohme Corp. | Heterocyclic quinolizine derived m1 receptor positive allosteric modulators |
| WO2011159554A1 (en) * | 2010-06-15 | 2011-12-22 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide m1 receptor positive allosteric modulators |
| WO2011159553A1 (en) | 2010-06-15 | 2011-12-22 | Merck Sharp & Dohme Corp. | Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators |
| WO2012003147A1 (en) | 2010-07-01 | 2012-01-05 | Merck Sharp & Dohme Corp. | Isoindolone m1 receptor positive allosteric modulators |
| WO2012158475A1 (en) | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | N-linked lactam m1 receptor positive allosteric modulators |
| US8940765B2 (en) | 2011-05-17 | 2015-01-27 | Merck Sharp & Dohme Corp. | N-linked quinolineamide M1 receptor positive allosteric modulators |
| US9284312B2 (en) | 2011-05-17 | 2016-03-15 | Merck Sharp & Dohme Corp. | N-methyl tetrahydroquinoline M1 receptor positive allosteric modulators |
| US9586964B2 (en) | 2011-10-28 | 2017-03-07 | Vanderbilt University | Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M1 |
| WO2013071201A1 (en) | 2011-11-11 | 2013-05-16 | Vanderbilt University | Substituted benzylspiroindolin-2-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| US9029563B2 (en) | 2012-01-06 | 2015-05-12 | Vanderbilt University | Substituted 1-benzylindolin-2-one analogs as positive allosteric modulators of muscarinic acetylcholine M1 receptors |
| WO2013106795A1 (en) * | 2012-01-12 | 2013-07-18 | Vanderbilt University | Substituted 4-(1h~pyrazol-4.yl)benzyl analogues as positive allosteric modulators of machr m1 receptors |
| JP6211509B2 (ja) | 2012-03-02 | 2017-10-11 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| JP6211530B2 (ja) | 2012-11-19 | 2017-10-11 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| AU2016276139B2 (en) | 2015-06-08 | 2018-07-19 | Suven Life Sciences Limited | Muscarinic M1 receptor positive allosteric modulators |
| BR112017026561A2 (pt) * | 2015-06-09 | 2018-08-14 | Bayer Pharma Aktiengesellschaft | moduladores alostéricos positivos do receptor muscarínico m2 |
| WO2017042643A1 (en) | 2015-09-10 | 2017-03-16 | Suven Life Sciences Limited | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators |
| WO2017155816A1 (en) * | 2016-03-09 | 2017-09-14 | Merck Sharp & Dohme Corp. | Quinazoline compounds useful as m1 receptor positive allosteric modulators |
| US11523858B2 (en) | 2017-08-11 | 2022-12-13 | Bradley D. Vilims | System and method for RF ablation with generated images of ablated tissue lesions |
| CN111018778B (zh) * | 2019-12-30 | 2020-11-06 | 杭州师范大学 | 一种喹诺酮类衍生物及其制备方法和应用 |
| US20250064833A1 (en) | 2021-12-13 | 2025-02-27 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1175836A (en) | 1977-09-20 | 1984-10-09 | Marcel Pesson | Production of 1,4-dihydroquinoline-3-carboxylic acid derivatives |
| JPS5845426B2 (ja) | 1978-09-29 | 1983-10-08 | 杏林製薬株式会社 | 置換キノリンカルボン酸誘導体 |
| US4914110A (en) * | 1984-05-11 | 1990-04-03 | Societe De Conseils De Recherches Et D'applications Scientifiques | Quinoline derivatives, their preparation and therapeutic compositions containing the same |
| US4623650A (en) | 1984-12-06 | 1986-11-18 | Pfizer Inc. | Antibiotic derivatives of 7-phenyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids |
| JPS61218584A (ja) | 1985-03-23 | 1986-09-29 | Hokuriku Seiyaku Co Ltd | キノリン−３−カルボン酸誘導体 |
| JP2831000B2 (ja) * | 1988-03-03 | 1998-12-02 | 大日本製薬株式会社 | （２−アミノベンゾイル）酢酸エステル誘導体 |
| FR2674247B1 (fr) | 1991-03-19 | 1993-07-16 | Bouchara Sa | Nouvelles quinolones fluorees, leur procede de preparation et les compositions pharmaceutiques en renfermant. |
| FR2675144B1 (fr) | 1991-04-10 | 1995-06-16 | Bouchara Sa | Nouvelles quinolones difluorees - leur procede de preparation et les compositions pharmaceutiques en renfermant. |
| TW301607B (de) | 1993-03-09 | 1997-04-01 | Takeda Pharm Industry Co Ltd | |
| WO1997040846A1 (en) | 1996-04-30 | 1997-11-06 | Takeda Chemical Industries, Ltd. | COMBINED USE OF GnRH AGONIST AND ANTAGONIST |
| JP2000103707A (ja) * | 1998-09-28 | 2000-04-11 | Permachem Asia Ltd | 工業用殺菌剤 |
| US6583153B2 (en) | 2000-12-12 | 2003-06-24 | Ortho-Mcneil Pharmaceutical, Inc. | 7-heterocyclyl quinoline and thieno[2,3-b]yridine derivatives useful as antagonists of gonadotropin releasing hormone |
| DE10108271A1 (de) | 2001-02-21 | 2002-08-22 | Schering Ag | Chinolin-, Isochinolin- und Phthalazinderivate als Antagonisten des Gonadotropin freisetzenden Hormons |
| SE0101256D0 (sv) * | 2001-04-06 | 2001-04-06 | A & Science Invest Ab | Treatment of low back pain |
| CN1652784A (zh) * | 2002-05-14 | 2005-08-10 | 加利福尼亚大学董事会 | 取代的喹诺酮羧酸、它们的衍生物、作用部位、以及其用途 |
| TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| MXPA06000675A (es) | 2003-07-24 | 2006-04-19 | Astellas Pharma Inc | Derivado de quinolona o sal del mismo. |
| US7498341B2 (en) | 2004-01-31 | 2009-03-03 | Sanofi Aventis Deutschland Gmbh | Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
| WO2005087759A1 (en) | 2004-03-10 | 2005-09-22 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Qiunolin-4-ones as inhibitors of retroviral integrase for the treatment of hiv, aids and aids related complex (arc) |
| EP2522670A1 (de) * | 2004-04-07 | 2012-11-14 | Takeda Pharmaceutical Company Limited | Heterozyklische CRF-Rezeptor-Antagonisten |
| JP2006117555A (ja) | 2004-10-20 | 2006-05-11 | Kyorin Pharmaceut Co Ltd | １−トリフルオロメチル−４−キノロンカルボン酸誘導体 |
| JP4858683B2 (ja) | 2005-01-20 | 2012-01-18 | アステラス製薬株式会社 | キノロン誘導体又はその塩の製造法 |
| JP2008094720A (ja) | 2005-01-20 | 2008-04-24 | Astellas Pharma Inc | キノロン誘導体のプロドラッグ又はその塩 |
| JP4853824B2 (ja) | 2005-01-20 | 2012-01-11 | アステラス製薬株式会社 | キノロン誘導体を有効成分とする医薬組成物 |
-
2006
- 2006-12-04 DE DE602006015851T patent/DE602006015851D1/de active Active
- 2006-12-04 AU AU2006322045A patent/AU2006322045A1/en not_active Abandoned
- 2006-12-04 WO PCT/US2006/046262 patent/WO2007067489A1/en not_active Ceased
- 2006-12-04 CA CA002631917A patent/CA2631917A1/en not_active Abandoned
- 2006-12-04 JP JP2008543538A patent/JP5192389B2/ja not_active Expired - Fee Related
- 2006-12-04 WO PCT/US2006/046332 patent/WO2007100366A2/en not_active Ceased
- 2006-12-04 EP EP06838942A patent/EP1963271B1/de not_active Ceased
- 2006-12-04 US US11/920,717 patent/US8389545B2/en active Active
- 2006-12-04 AT AT06838942T patent/ATE475650T1/de not_active IP Right Cessation
-
2007
- 2007-04-04 TW TW096112153A patent/TW200840814A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8389545B2 (en) | 2013-03-05 |
| WO2007100366A2 (en) | 2007-09-07 |
| WO2007100366A3 (en) | 2007-11-29 |
| CA2631917A1 (en) | 2007-06-14 |
| AU2006322045A1 (en) | 2007-06-14 |
| JP2009518309A (ja) | 2009-05-07 |
| WO2007067489A1 (en) | 2007-06-14 |
| JP5192389B2 (ja) | 2013-05-08 |
| TW200840814A (en) | 2008-10-16 |
| US20100317692A1 (en) | 2010-12-16 |
| EP1963271B1 (de) | 2010-07-28 |
| DE602006015851D1 (de) | 2010-09-09 |
| EP1963271A1 (de) | 2008-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE475650T1 (de) | Positive allosterische chinolon-m1- rezeptormodulatoren | |
| ATE530544T1 (de) | Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren | |
| TN2011000209A1 (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| TN2012000231A1 (en) | Quinoline amide m1 receptor positive allosteric modulators | |
| BR0316350A (pt) | Diaminotriazóis úteis como inibidores de proteìna cinases | |
| EP2582676A4 (de) | Positive allosterische tetrahydrochinolin-amid-m1-rezeptormodulatoren | |
| MX2012002583A (es) | Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1. | |
| TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
| EA200901373A1 (ru) | Аминогетероциклические соединения | |
| CY1110965T1 (el) | Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου | |
| EA201071245A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс | |
| TW200716546A (en) | Oxindole compounds and their uses as therapeutic agents | |
| ATE396973T1 (de) | Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit | |
| EA200700489A1 (ru) | Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств | |
| EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
| CY1111070T1 (el) | Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace) | |
| TW200800976A (en) | New compounds for the treatment of neurological, psychiatric or pain disorders | |
| ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| EA200600971A1 (ru) | Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона | |
| DE602006006712D1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
| ATE552257T1 (de) | Positive allosterische chinolizidinon-m1- rezeptormodulatoren | |
| EA200600071A1 (ru) | Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором | |
| ATE538796T1 (de) | Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit | |
| WO2009117283A3 (en) | Quinolizidinone m1 receptor positive allosteric modulators | |
| EA200801302A1 (ru) | Композиции и способы лечения нарушений цнс |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |